Literature DB >> 33657133

Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure.

Paul McCusker1,2, Claudia M Rohr1, John D Chan1,3,4.   

Abstract

Control of the neglected tropical disease schistosomiasis relies almost entirely on praziquantel (PZQ) monotherapy. How PZQ clears parasite infections remains poorly understood. Many studies have examined the effects of PZQ on worms cultured in vitro, observing outcomes such as muscle contraction. However, conditions worms are exposed to in vivo may vary considerably from in vitro experiments given the short half-life of PZQ and the importance of host immune system engagement for drug efficacy in animal models. Here, we investigated the effects of in vivo PZQ exposure on Schistosoma mansoni. Measurement of pro-apoptotic caspase activation revealed that worm death occurs only after parasites shift from the mesenteric vasculature to the liver, peaking 24 hours after drug treatment. This indicates that PZQ is not directly schistocidal, since PZQ's half-life is ~2 hours in humans and ~30 minutes in mice, and focuses attention on parasite interactions with the host immune system following the shift of worms to the liver. RNA-Seq of worms harvested from mouse livers following sub-lethal PZQ treatment revealed drug-evoked changes in the expression of putative immunomodulatory and anticoagulant gene products. Several of these gene products localized to the schistosome esophagus and may be secreted into the host circulation. These include several Kunitz-type protease inhibitors, which are also found in the secretomes of other blood feeding animals. These transcriptional changes may reflect mechanisms of parasite immune-evasion in response to chemotherapy, given the role of complement-mediated attack and the host innate/humoral immune response in parasite elimination. One of these isoforms, SmKI-1, has been shown to exhibit immunomodulatory and anti-coagulant properties. These data provide insight into the effect of in vivo PZQ exposure on S. mansoni, and the transcriptional response of parasites to the stress of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33657133      PMCID: PMC7959349          DOI: 10.1371/journal.pntd.0009200

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  73 in total

1.  Anticoagulants from hematophagous animals.

Authors:  Cho Yeow Koh; R Manjunatha Kini
Journal:  Expert Rev Hematol       Date:  2008-12       Impact factor: 2.929

Review 2.  Macrophage activation governs schistosomiasis-induced inflammation and fibrosis.

Authors:  Luke Barron; Thomas A Wynn
Journal:  Eur J Immunol       Date:  2011-09       Impact factor: 5.532

3.  Kunitz-type protease inhibitor as a vaccine candidate against schistosomiasis mansoni.

Authors:  Shiwanthi L Ranasinghe; Mary Duke; Marina Harvie; Donald P McManus
Journal:  Int J Infect Dis       Date:  2017-11-08       Impact factor: 3.623

4.  In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study.

Authors:  H Mehlhorn; B Becker; P Andrews; H Thomas; J K Frenkel
Journal:  Arzneimittelforschung       Date:  1981

5.  Interaction of an esophageal MEG protein from schistosomes with a human S100 protein involved in inflammatory response.

Authors:  Débora Orcia; Ana Eliza Zeraik; José L S Lopes; Joci N A Macedo; Clarissa Romano Dos Santos; Katia C Oliveira; Leticia Anderson; B A Wallace; Sergio Verjovski-Almeida; Ana P U Araujo; Ricardo DeMarco
Journal:  Biochim Biophys Acta Gen Subj       Date:  2016-09-15       Impact factor: 3.770

6.  Human IgG1 Responses to Surface Localised Schistosoma mansoni Ly6 Family Members Drop following Praziquantel Treatment.

Authors:  Iain W Chalmers; Colin M Fitzsimmons; Martha Brown; Christine Pierrot; Frances M Jones; Jakub M Wawrzyniak; Narcis Fernandez-Fuentes; Edridah M Tukahebwa; David W Dunne; Jamal Khalife; Karl F Hoffmann
Journal:  PLoS Negl Trop Dis       Date:  2015-07-06

7.  The Extracellular Vesicles of the Helminth Pathogen, Fasciola hepatica: Biogenesis Pathways and Cargo Molecules Involved in Parasite Pathogenesis.

Authors:  Krystyna Cwiklinski; Eduardo de la Torre-Escudero; Maria Trelis; Dolores Bernal; Philippe J Dufresne; Gerard P Brennan; Sandra O'Neill; Jose Tort; Steve Paterson; Antonio Marcilla; John P Dalton; Mark W Robinson
Journal:  Mol Cell Proteomics       Date:  2015-10-20       Impact factor: 5.911

8.  Developmentally regulated expression, alternative splicing and distinct sub-groupings in members of the Schistosoma mansoni venom allergen-like (SmVAL) gene family.

Authors:  Iain W Chalmers; Andrew J McArdle; Richard Mr Coulson; Marissa A Wagner; Ralf Schmid; Hirohisa Hirai; Karl F Hoffmann
Journal:  BMC Genomics       Date:  2008-02-23       Impact factor: 3.969

9.  The esophageal gland mediates host immune evasion by the human parasite Schistosoma mansoni.

Authors:  Jayhun Lee; Tracy Chong; Phillip A Newmark
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-31       Impact factor: 11.205

10.  Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice.

Authors:  Gordana Panic; Marie-Thérèse Ruf; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

View more
  2 in total

1.  Translating From Egg- to Antigen-Based Indicators for Schistosoma mansoni Elimination Targets: A Bayesian Latent Class Analysis Study.

Authors:  Jessica Clark; Arinaitwe Moses; Andrina Nankasi; Christina L Faust; Moses Adriko; Diana Ajambo; Fred Besigye; Arron Atuhaire; Aidah Wamboko; Candia Rowel; Lauren V Carruthers; Rachel Francoeur; Edridah M Tukahebwa; Poppy H L Lamberton; Joaquin M Prada
Journal:  Front Trop Dis       Date:  2022-02-18

Review 2.  High-content approaches to anthelmintic drug screening.

Authors:  Mostafa Zamanian; John D Chan
Journal:  Trends Parasitol       Date:  2021-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.